MedTrace Logo

Biomarkers in Autosomal Dominant Cerebellar Ataxia

NCT01470729 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 102

Last updated 2019-09-06

No results posted yet for this study

Summary

Autosomal dominant cerebellar ataxias (ADCA) are a group of neurodegenerative disorders that are clinically and genetically various. BIOSCA study aims to identify markers of the metabolism (energy production inside the cells) in the blood and the brain of ADCA 1,2,3 and 7 patients and control subjects, in the perspective of future therapeutic trials.

Conditions

  • Spinocerebellar Ataxia Type 1
  • Spinocerebellar Ataxia Type 2
  • Spinocerebellar Ataxia, Autosomal Recessive 3
  • Episodic Ataxia, Type 7

Interventions

OTHER

metabolic and imaging biomarkers in SCA1,2,3 and 7 patients

MRI, a bone mineral density and a resting metabolic rate assessments, as well as donating fasted blood samples

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Alexandra DURR, PhD · Assistance Publique - Hôpitaux de Paris

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01470729 on ClinicalTrials.gov